BioNexus Gene Lab (BGLC) Interest Expenses (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Interest Expenses data on file, last reported at $12.2 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 21.29% year-over-year to $12.2 million; the trailing twelve-month figure through Mar 2026 stood at $12.2 million (up 21.29% YoY), and the FY2025 full-year result was $11.6 million, up 20408.1% from the prior year.
• Interest Expenses advanced to $12.2 million in Q1 2026, from -$42112.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $12.2 million in Q1 2026 to a low of -$42112.0 in Q4 2025.
• A 5-year average of $1.3 million and a median of $4480.0 in 2024 frame the typical range for Interest Expenses.
• Peak annual rise in Interest Expenses reached 96523.0% in 2025, while the deepest fall reached 397.15% in 2025.
• Tracing BGLC's Interest Expenses over 5 years: stood at -$4762.0 in 2022, then soared by 187.84% to $4183.0 in 2023, then surged by 238.8% to $14172.0 in 2024, then sank by 397.15% to -$42112.0 in 2025, then surged by 28979.25% to $12.2 million in 2026.
• Business Quant data shows BGLC's Interest Expenses at $12.2 million in Q1 2026, -$42112.0 in Q4 2025, and $54570.0 in Q3 2025.